The protocol at a glance
In China's GLORY-1 trial, people stepped up over 8 weeks to a weekly 4 mg or 6 mg injection and stayed there to week 48. GLORY-2 tested 9 mg for 60 weeks.
| Weeks (GLORY-1) | Weekly amount |
|---|---|
| 1-4 | 2 mg (both groups) |
| 5-8 | 4 mg (both groups) |
| 9-48 | 4 mg group stays on 4 mg; 6 mg group goes up to 6 mg |
| GLORY-2 (60 weeks) | 9 mg target; the step-up plan was not in the sources I checked |
GLORY-1 schedule is from the ClinicalTrials.gov entry NCT05607680. The 4 mg group was 2 mg for 4 weeks, then 4 mg for 44 weeks. The 6 mg group was 2 mg, 4 mg, then 6 mg for 40 weeks. This is a trial schedule. The Chinese label was not read, so check it for the exact approved doses.
Community notes usually follow the GLORY trial doses, stepping up weekly to 4 to 6 mg. This is community talk, not a label.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing calculator
Enter the vial size, the water you add and the amount you want to draw; it gives the mark on a 100-unit (1 mL) insulin syringe.
What the trials found
GLORY-1: 610 adults in China with overweight or obesity, 48 weeks. GLORY-2: 461 adults with obesity, 60 weeks. Average body weight change (treatment-policy analysis):
Ji L et al. N Engl J Med 2025 (GLORY-1, NCT05607680). JAMA 2026 (GLORY-2, NCT06164873). Both trials were in Chinese adults, so results may differ elsewhere.
Side effects
- Stomach and gut effects were the most common. In GLORY-2, 53% had vomiting, 47% nausea and 39% diarrhea on 9 mg, versus 1%, 3% and 6% on placebo. Most were mild to moderate.
- In GLORY-1, 1.5% (4 mg) and 0.5% (6 mg) stopped because of side effects, versus 1.0% on placebo. In GLORY-2, 2.9% stopped on 9 mg.
How it works
GLP-1 receptor
Like semaglutide, it switches on the GLP-1 receptor, which lowers appetite.
Glucagon receptor
It also switches on the glucagon receptor. This is why it is called a dual agonist.
Sources
- Ji L et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med 2025 (GLORY-1), NCT05607680
- Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity (GLORY-2). JAMA 2026, NCT06164873
- ClinicalTrials.gov NCT05607680 (arm schedule)
- Innovent press release via PR Newswire / PharmaFocus Asia, 30 June 2025 (NMPA approval for chronic weight management in adults with BMI 28+ or 24+ with a related condition)